Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells.

Abstract:

:Glucocorticoid (GC) receptor (GR) phosphorylation and signature genes were studied in chronic lymphocytic leukemia (CLL) cells to help place GCs within modern treatment algorithms. In contrast to normal B and T cells, transcription of GC-regulated genes was not rhythmic and the synthetic GC dexamethasone (DEX) could not inhibit toll-like receptor (TLR)-responses in CLL cells. This intrinsic GC-resistance was associated with aberrant GR-phosphorylation on activating Ser211 and inhibitory Ser226 sites. Ibrutinib increased transcription of the GR-signature gene GILZ in circulating CLL cells along with GR(pS211)/GR(pS226) ratios and lytic sensitivity to DEX that were not reversed by the competitive antagonist mifepristone in vitro. However, ibrutinib could not improve GR-responses in circulating CLL cells activated with IL2 and TLR7/8 agonists to mimic conditions in pseudofollicle microenvironments. Addition of the janus kinase inhibitor ruxolitinib to block ibrutinib-insensitive signals increased GILZ transcription in pseudofollicle conditions in vitro and in a clinical trial (NCT02912754), and also increased GR(S211)/GR(S226) ratios and DEX-mediated killing in patient samples in vitro. These observations suggest that intrinsic resistance to endogenous GCs is characteristic of CLL cells and ibrutinib may help increase the therapeutic activity of GCs by non-canonical activation of GR.

journal_name

Leukemia

journal_title

Leukemia

authors

Shi Y,Wang G,Muhowski EM,McCaw L,Wang C,Bjarnason G,Woyach JA,Spaner DE

doi

10.1038/s41375-019-0381-4

subject

Has Abstract

pub_date

2019-07-01 00:00:00

pages

1650-1662

issue

7

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-019-0381-4

journal_volume

33

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.

    abstract::MUM1 (multiple myeloma oncogene 1)/IRF4 (interferon regulatory factor 4) is a transcription factor that is activated as a result of t(6;14)(p25;q32) in multiple myeloma. MUM1 expression is seen in various B-cell lymphomas and predicts an unfavorable outcome in some lymphoma subtypes. To elucidate its role in B-cell ma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403833

    authors: Uranishi M,Iida S,Sanda T,Ishida T,Tajima E,Ito M,Komatsu H,Inagaki H,Ueda R

    更新日期:2005-08-01 00:00:00

  • Facilitated engraftment of human hematopoietic cells in severe combined immunodeficient mice following a single injection of Cl2MDP liposomes.

    abstract::Transplantation of normal and malignant human hematopoietic cells into severe combined immunodeficient (SCID) mice allows for evaluation of long-term growth abilities of these cells and provides a preclinical model for therapeutic interventions. However, large numbers of cells are required for successful engraftment i...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400694

    authors: Terpstra W,Leenen PJ,van den Bos C,Prins A,Loenen WA,Verstegen MM,van Wyngaardt S,van Rooijen N,Wognum AW,Wagemaker G,Wielenga JJ,Löwenberg B

    更新日期:1997-07-01 00:00:00

  • The regulation of hematopoiesis in max 41 transgenic mice with sustained excess granulopoiesis.

    abstract::max 41 transgenic mice consistently exhibit elevated numbers of mature granulocytes and monocytes in the peripheral blood and of immature and mature cells of these lineages in the marrow, spleen, lymph nodes and liver. The immature populations are not autonomous and exhibit a normal quantitative responsiveness to prol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Metcalf D,Roberts AW,Willson TA

    更新日期:1996-02-01 00:00:00

  • Clinical activity of arsenic trioxide for the treatment of multiple myeloma.

    abstract::Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parasitic infections. In the early 1990s, reports from China described impressive results with arsenic trioxide in patients with de novo, rela...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2402599

    authors: Munshi NC,Tricot G,Desikan R,Badros A,Zangari M,Toor A,Morris C,Anaissie E,Barlogie B

    更新日期:2002-09-01 00:00:00

  • A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies.

    abstract::To guide development of new clinical strategies, a review of recent investigations in the pathobiology of MDS was performed. Articles were identified through a Medline search. Studies, including reviews, are cited in the references. A multistep pathogenesis is proposed. (1) Targeted injury or mutation within hemopoiet...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401618

    authors: Rosenfeld C,List A

    更新日期:2000-01-01 00:00:00

  • CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets.

    abstract::The activation of natural killer (NK) cells leads to degranulation and secretion of cytotoxic granula. During this process, the lytic granule membrane protein CD107a becomes detectable at the cell surface. Based on this phenomenon, we have analyzed by a novel flow cytometry-based assay, the number and phenotype of NK ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403704

    authors: Penack O,Gentilini C,Fischer L,Asemissen AM,Scheibenbogen C,Thiel E,Uharek L

    更新日期:2005-05-01 00:00:00

  • Growth and differentiation of a murine interleukin-3-producing myelomonocytic leukemia cell line in a protein-free chemically defined medium.

    abstract::We established the continuous growth of WEHI-3B D+ cells in protein-free chemically defined F-12 medium by stepwise decreases in the concentration of fetal calf serum. This cell line, designated as WEHI-3B-Y1, has now been propagated in protein-free F-12 medium for 3 years. The population-doubling time of the cells in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Kajigaya Y,Ikuta K,Sasaki H,Matsuyama S

    更新日期:1990-10-01 00:00:00

  • Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.

    abstract::Neutropenia-related fungal infections can be life-threatening despite antifungal therapy. We evaluated the role of recombinant granulocyte colony-stimulating factor (rG-CSF)-elicited white blood cell (WBC) transfusions in patients with neutropenia-related fungal infections. Adult patients with hematologic malignancies...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2400811

    authors: Dignani MC,Anaissie EJ,Hester JP,O'Brien S,Vartivarian SE,Rex JH,Kantarjian H,Jendiroba DB,Lichtiger B,Andersson BS,Freireich EJ

    更新日期:1997-10-01 00:00:00

  • Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.

    abstract::Patients with acute myelogenous leukemia or myelodysplastic syndrome may respond to farnesyl transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients. FTIs prevent the attachment of a lipid farnesyl moiety to dependent proteins prior to their insertion into the plasma m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403063

    authors: Liesveld JL,Lancet JE,Rosell KE,Menon A,Lu C,McNair C,Abboud CN,Rosenblatt JD

    更新日期:2003-09-01 00:00:00

  • Prognostic impact of RAS-pathway mutations in patients with myelofibrosis.

    abstract::RAS-pathway mutations are recurrent events in myeloid malignancies. However, there is limited data on the significance of RAS-pathway mutations in patients with myelofibrosis (MF). We analyzed next-generation sequencing data of 16 genes, including RAS-pathway genes, from 723 patients with primary and secondary MF acro...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-019-0603-9

    authors: Santos FPS,Getta B,Masarova L,Famulare C,Schulman J,Datoguia TS,Puga RD,Alves Paiva RM,Arcila ME,Hamerschlak N,Kantarjian HM,Levine RL,Campregher PV,Rampal RK,Verstovsek S

    更新日期:2020-03-01 00:00:00

  • The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.

    abstract::In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/sj.leu.2405090

    authors: Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

    更新日期:2008-03-01 00:00:00

  • Suppression of G-CSF-mediated Stat signalling by IL-3.

    abstract::G-CSF-induced myeloid differentiation of 32Dcl3 murine myeloblast cells is antagonized by concurrent exposure to interleukin-3 (IL-3) or by oncogenic transformation of 32Dcl3 by src- or abl-oncogenes which render the cells IL-3-independent. Recent reports have linked G-CSF-mediated differentiation to the ability of G-...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401253

    authors: Steinman RA,Iro A

    更新日期:1999-01-01 00:00:00

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

    abstract::We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404653

    authors: Suela J,Alvarez S,Cifuentes F,Largo C,Ferreira BI,Blesa D,Ardanaz M,García R,Marquez JA,Odero MD,Calasanz MJ,Cigudosa JC

    更新日期:2007-06-01 00:00:00

  • Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.

    abstract::The majority of neutralizing antibodies of HTLV-I are directed against linear epitopes of the envelope surface glycoprotein (gp46) in the immunodominant region 175-199. Although gp46 presents a remarkable degree of conservation, the substitution of the proline at position 192 by a serine is described for 10 isolates a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Londos-Gagliardi D,Armengaud MH,Freund F,Dalibart R,Moze E,Huet S,Legrand E,Guillemain BJ

    更新日期:1997-04-01 00:00:00

  • Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

    abstract::Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT) has been shown to be predictive for graft failure and relapse. We have explored the impact of a novel approach for the quantitative determination of chimerism using a commercial PCR assay with multiplex amplification of nine STR-l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401953

    authors: Thiede C,Bornhäuser M,Oelschlägel U,Brendel C,Leo R,Daxberger H,Mohr B,Florek M,Kroschinsky F,Geissler G,Naumann R,Ritter M,Prange-Krex G,Lion T,Neubauer A,Ehninger G

    更新日期:2001-02-01 00:00:00

  • Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay.

    abstract::We have used a 4-day MTT colorimetric assay to study drug sensitivity of leucocytes from leukaemia patients and from normal donors. Response to Adriamycin, vincristine, aclacinomycin A, 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2), and melphalan has been determined, together with the effects of the r...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lambert E,Rees JK,Twentyman PR

    更新日期:1992-10-01 00:00:00

  • The oncogenicity of Jun.

    abstract::A mutational analysis of the delta region of the Jun protein shows an inverse correlation between transforming and transactivation potential of the mutant proteins if both properties are measured in chicken embryo fibroblasts. The possibility that Jun acquires oncogenicity not by gain but by loss of function is also s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Vogt PK,Morgan IM,Håvarstein L,Su H,Hartl M,Schuur E

    更新日期:1992-01-01 00:00:00

  • B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.

    abstract::Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response. Furthermore, these treatments can have notable morbidity and are not uniformly tolerated in all patients. As there i...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0734-z

    authors: Shah N,Chari A,Scott E,Mezzi K,Usmani SZ

    更新日期:2020-04-01 00:00:00

  • Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1.

    abstract::We have examined interactions between the purine nucleoside analog fludarabine (9-beta-arabinofuranosyl-2-fluoroadenine) and the macrocyclic lactone bryostatin 1 in the human monocytic leukemic cell line U937. Fludarabine exerted dose-dependent effects on U937 cell viability and growth which were associated with both ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401454

    authors: Vrana JA,Wang Z,Rao AS,Tang L,Chen JH,Kramer LB,Grant S

    更新日期:1999-07-01 00:00:00

  • MEIS 1 expression is downregulated through promoter hypermethylation in AML1-ETO acute myeloid leukemias.

    abstract::Retroviral insertional mutagenesis in BXH2 mice commonly induces myeloid leukemias. One of the most frequently involved genes in experimental studies is Meis 1. In contrast to other genes in murine models, Meis 1 has not been affected by recurrent chromosomal translocations or point mutations in human leukemias. We fo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403377

    authors: Lasa A,Carnicer MJ,Aventín A,Estivill C,Brunet S,Sierra J,Nomdedéu JF

    更新日期:2004-07-01 00:00:00

  • PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)α and allows fatty acids to be used as fuel. However, the role of PPARα in CLL is unclear. PPARα wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.329

    authors: Spaner DE,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

    更新日期:2013-04-01 00:00:00

  • Anti-angiogenic activity of the purine analog 6-thioguanine.

    abstract::The antimetabolite 6-thioguanine (6-TG) is utilized in the management of acute myelogenous leukemia (AML). Angiogenesis is a possible therapeutic target in hematologic tumors. Thus, we addressed the possibility that 6-TG may also act as an anti-angiogenic molecule. 6-TG inhibited endothelial cell proliferation trigger...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402646

    authors: Presta M,Belleri M,Vacca A,Ribatti D

    更新日期:2002-08-01 00:00:00

  • NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

    abstract::Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/leu.2010.205

    authors: Clappier E,Collette S,Grardel N,Girard S,Suarez L,Brunie G,Kaltenbach S,Yakouben K,Mazingue F,Robert A,Boutard P,Plantaz D,Rohrlich P,van Vlierberghe P,Preudhomme C,Otten J,Speleman F,Dastugue N,Suciu S,Benoit Y,B

    更新日期:2010-12-01 00:00:00

  • Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.

    abstract::Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to de...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403719

    authors: Zeiser R,Spyridonidis A,Wäsch R,Ihorst G,Grüllich C,Bertz H,Finke J

    更新日期:2005-05-01 00:00:00

  • Characterization of the blast cells in acute leukemia with translocation (4;11): report of eight additional cases and of one case with a variant translocation.

    abstract::Eight new cases (five adults and three children) of acute leukemia characterized by the presence in bone marrow cells of a t(4;11)(q21;q23)and one similar case, a child, with a t(1;11)(p32;q23) are reported. All patients were diagnosed as having acute lymphoblastic leukemia (ALL) with high-risk features. Immunological...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hagemeijer A,van Dongen JJ,Slater RM,van't Veer MB,Behrendt H,Hählen K,Sizoo W,Abels J

    更新日期:1987-01-01 00:00:00

  • Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.

    abstract::Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects ...

    journal_title:Leukemia

    pub_type: 杂志文章,meta分析,评审

    doi:10.1038/s41375-020-01016-0

    authors: Ludwig H,Boccadoro M,Moreau P,San-Miguel J,Cavo M,Pawlyn C,Zweegman S,Facon T,Driessen C,Hajek R,Dimopoulos MA,Gay F,Avet-Loiseau H,Terpos E,Zojer N,Mohty M,Mateos MV,Einsele H,Delforge M,Caers J,Weisel K,Jackso

    更新日期:2021-01-01 00:00:00

  • Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

    abstract::The cell line described here was established for a 50-year-old male patient with rapidly progressive non-Hodgkin's lymphoma whose marrow was diffusely infiltrated with large granular lymphocytes (LGL). Immunophenotyping of marrow blasts and peripheral lymphocytes was positive for CD56, CD2 and CD7, and negative for CD...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gong JH,Maki G,Klingemann HG

    更新日期:1994-04-01 00:00:00

  • The TLR1/2 agonist PAM(3)CSK(4) instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

    abstract::Toll-like receptors (TLRs) constitute a family of nonpolymorphic receptors that are devoted to pathogen recognition. In this work, we have explored the impact of TLR ligands (TLR-L) on human hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). We show that HSCs and HPCs have a comparable pattern ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2009.155

    authors: De Luca K,Frances-Duvert V,Asensio MJ,Ihsani R,Debien E,Taillardet M,Verhoeyen E,Bella C,Lantheaume S,Genestier L,Defrance T

    更新日期:2009-11-01 00:00:00

  • Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

    abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title:Leukemia

    pub_type: 已发布勘误

    doi:10.1038/s41375-020-0968-9

    authors: Prutsch N,Gurnhofer E,Suske T,Liang HC,Schlederer M,Roos S,Wu LC,Simonitsch-Klupp I,Alvarez-Hernandez A,Kornauth C,Leone DA,Svinka J,Eferl R,Limberger T,Aufinger A,Shirsath N,Wolf P,Hielscher T,Sternberg C,Aberger F

    更新日期:2020-11-01 00:00:00

  • Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital.

    abstract::We present the long-term results of three consecutive clinical trials (Total Therapy studies 11, 12 and 13A) conducted for children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1984 and 1994. In study 11 (1984-1988), the overall event-free survival rates (+/-1 s.e.) were 71.8 +/- 2.4% and 69.3 +/- 2...

    journal_title:Leukemia

    pub_type: 杂志文章,meta分析

    doi:10.1038/sj.leu.2401938

    authors: Pui CH,Boyett JM,Rivera GK,Hancock ML,Sandlund JT,Ribeiro RC,Rubnitz JE,Behm FG,Raimondi SC,Gajjar A,Razzouk B,Campana D,Kun LE,Relling MV,Evans WE

    更新日期:2000-12-01 00:00:00